Gay men’s PrEP study final results: near 90% efficacy in men who took drug, but adherence even lower than thought
A completed series of investigations into the iPrEx study of tenofovir/FTC(Truvada) at pre-exposure prophylaxis (PrEP) has found that the drug was 87% efficacious in preventing HIV infection amongst those who had detectable drug levels, though only 42% efficacious overall.
An expanded number of drug-level tests show that only 44% of those who did not become infected with HIV had drug detectable in their blood and/or cells, suggesting that overall adherence in the study was even lower than thought. This suggests that adherence will be the factor that may limit the effectiveness of this strategy in curbing HIV in many populations, and that it may need to be offered only to people highly motivated to take it.
Similar Posts:
- Concerns about efficacy, cost and side-effects possible barriers to PrEP uptake in groups with high HIV risk
- Elevated CD8 cell count associated with HIV treatment failure
- HIV treatment in primary infection: 48 week course modestly delays CD4 drop
- Herpes drugs and viral load: valaciclovir works better than aciclovir
- High genital HIV levels may persist in women who appear to achieve viral suppression with use of ART
